Literature DB >> 18437293

Paroxysmal nocturnal hemoglobinuria may cause retinal vascular occlusions.

Alexander F Scheuerle1, Nermin Serbecic, Sven C Beutelspacher.   

Abstract

BACKGROUND: Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by the classic triad of haemolytic anaemia, thrombophilia and cytopenia with the majority of cases occurring in adulthood. PNH constitutes a nonmalignant clonal disease of hematopoietic stem cells harboring somatic mutations in the X-linked phosphatidyl inositol glycan complementation group-A (PIG-A) gene.
METHODS: We report for the first time retinal venous vascular occlusion as the primary manifestation of PNH. A patient of untypical age for retinal vascular occlusions presented with a history of 4 weeks of progressive reduction in visual acuity.
RESULTS: The screening tests for thrombophilia were not successful. However, elevated LDH was detected, leading to the diagnosis of PNH.
CONCLUSIONS: To date, no report shows retinal vascular occlusion as the primary symptom leading to the diagnosis PNH. This article describes, for the first time, that this rare disease needs to be considered in the differential diagnosis of retinal vascular occlusions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18437293     DOI: 10.1007/s10792-007-9188-9

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  14 in total

Review 1.  Diagnosis and management of paroxysmal nocturnal hemoglobinuria.

Authors:  Charles Parker; Mitsuhiro Omine; Stephen Richards; Jun-Ichi Nishimura; Monica Bessler; Russell Ware; Peter Hillmen; Lucio Luzzatto; Neal Young; Taroh Kinoshita; Wendell Rosse; Gerard Socié
Journal:  Blood       Date:  2005-07-28       Impact factor: 22.113

2.  Eculizumab in paroxysmal nocturnal hemoglobinuria.

Authors:  Morihito Takita; Tomoko Matsumura; Masahiro Kami
Journal:  N Engl J Med       Date:  2006-12-28       Impact factor: 91.245

3.  Eculizumab in paroxysmal nocturnal hemoglobinuria.

Authors:  Yuri B Pride
Journal:  N Engl J Med       Date:  2006-12-28       Impact factor: 91.245

4.  Eculizumab in paroxysmal nocturnal hemoglobinuria.

Authors:  Satheesh K Kathula
Journal:  N Engl J Med       Date:  2006-12-28       Impact factor: 91.245

5.  Bilateral serous retinal detachment as the first manifestation of paroxysmal nocturnal haemoglobinuria.

Authors:  M-H Song; Y-J Roh
Journal:  Eye (Lond)       Date:  2006-09-22       Impact factor: 3.775

Review 6.  Paroxysmal nocturnal haemoglobinuria: clinical manifestations, haematology, and nature of the disease.

Authors:  J V Dacie; S M Lewis
Journal:  Ser Haematol       Date:  1972

7.  Differential usefulness of various markers in the flow cytometric detection of paroxysmal nocturnal hemoglobinuria in blood and bone marrow.

Authors:  Horatiu Olteanu; Nitin J Karandikar; Robert W McKenna; Yin Xu
Journal:  Am J Clin Pathol       Date:  2006-11       Impact factor: 2.493

8.  Cardiopulmonary bypass surgery in a patient with paroxysmal nocturnal haemoglobinuria.

Authors:  D Dinesh; B Baker; J M Carter
Journal:  Transfus Med       Date:  2006-06       Impact factor: 2.019

Review 9.  The role of complement regulatory proteins (CD55 and CD59) in the pathogenesis of autoimmune hemocytopenias.

Authors:  Alejandro Ruiz-Argüelles; Luis Llorente
Journal:  Autoimmun Rev       Date:  2006-10-16       Impact factor: 9.754

10.  Thrombosis in patients with paroxysmal noctural hemoglobinuria is associated with markedly elevated plasma levels of leukocyte-derived tissue factor.

Authors:  Howard A Liebman; Donald I Feinstein
Journal:  Thromb Res       Date:  2003       Impact factor: 3.944

View more
  4 in total

1.  Isolated central retinal artery occlusion as an initial presentation of paroxysmal nocturnal hemoglobinuria and successful long-term prevention of systemic thrombosis with eculizumab.

Authors:  Hyun Seung Yang; So Hyun Park; Jung Ran Choi; June-Gone Kim
Journal:  Jpn J Ophthalmol       Date:  2013-06-14       Impact factor: 2.447

2.  Retinal vein occlusion and paroxysmal nocturnal hemoglobinuria.

Authors:  Marc Sorigue; Jordi Juncà; Elisa Orna; Nevena Romanic; Edurne Sarrate; Jordi Castellvi; Montse Soler; Ines Rodríguez-Hernandez; Evarist Feliu; Susana Ruiz
Journal:  J Thromb Thrombolysis       Date:  2017-07       Impact factor: 2.300

3.  A novel hemoglobin-binding peptide reduces cell-free hemoglobin in murine hemolytic anemia.

Authors:  Madelyn S Hanson; Hao Xu; Timothy C Flewelen; Sandra L Holzhauer; Dawn Retherford; Deron W Jones; Anne C Frei; Kirkwood A Pritchard; Cheryl A Hillery; Neil Hogg; Nancy J Wandersee
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-11-02       Impact factor: 4.733

Review 4.  The state of complement in COVID-19.

Authors:  Behdad Afzali; Marina Noris; Bart N Lambrecht; Claudia Kemper
Journal:  Nat Rev Immunol       Date:  2021-12-15       Impact factor: 108.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.